Elevance Health, Inc. (NYSE: ELV), a leader in the healthcare plans industry, operates with a market capitalization of $85.39 billion, positioning itself as a formidable player within the U.S. healthcare sector. Known for its comprehensive health benefits and services, Elevance Health provides a wide range of offerings under its Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands.
Currently trading at $393.19, Elevance Health’s shares have experienced a steady trajectory within a 52-week range of $274.66 to $402.27. The stock’s recent price change remains flat, highlighting market stability amidst broader economic fluctuations. For investors looking at valuation, Elevance Health’s forward P/E ratio stands at 13.44, suggesting a reasonable valuation compared to industry peers, though other valuation metrics such as the trailing P/E and PEG ratios are not available for a more comprehensive comparison.
The company reports a modest revenue growth rate of 2.60%, which aligns with the steady demand for healthcare services. Despite limited data on net income, Elevance Health boasts a robust earnings per share (EPS) of 23.59, illustrating its ability to generate significant profits. The return on equity (ROE) of 12.09% further emphasizes the company’s efficiency in utilizing shareholder capital to drive growth.
Free cash flow, a critical indicator of financial health, amounts to just over $4.3 billion, providing Elevance Health with ample liquidity to invest in growth opportunities or return capital to shareholders. This is complemented by a sustainable dividend yield of 1.75% and a conservative payout ratio of 29.03%, ensuring that investors receive a steady income while the company retains earnings for reinvestment.
Analyst sentiment towards Elevance Health is notably positive, with 15 buy ratings and 7 hold ratings, and no sell recommendations. The average target price of $404.05 suggests a potential upside of 2.76%, indicating moderate optimism among analysts. The target price range spans from $331.00 to $498.00, reflecting varying degrees of confidence in the company’s growth prospects.
Technical indicators present a mixed picture. The stock’s 50-day moving average of $344.81 and a 200-day moving average of $334.72 suggest an upward trend, although the relative strength index (RSI) of 45.30 indicates that the stock is neither overbought nor oversold. The MACD and signal line values, at 13.00 and 15.62 respectively, warrant close monitoring for investors looking for entry or exit points.
Elevance Health’s diversified portfolio, spanning health benefits, pharmacy services, and specialty care, positions it well to capitalize on the growing demand for comprehensive healthcare solutions. As it continues to innovate and expand its offerings, the company remains a compelling consideration for investors seeking exposure to the healthcare sector. With its strategic positioning and commitment to enhancing health outcomes, Elevance Health is poised to navigate the complexities of the healthcare landscape and deliver long-term value to its shareholders.
